📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-06 14:04
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
16 announcements match the current filters (relevance ≥ 5).
45% PAT growth to ₹96 cr in Q1 FY27; Operational PAT up 9% on ₹356 cr sales
Procter & Gamble Health Limited (PGHL) reported a 7% YoY increase in sales to ₹356 crores for the quarter ended June 30, 2026. Reported Profit After Tax (PAT) surged 45% to ₹96 crores, significantly aided by one-time proceeds from the sale of an immovable asset. Excluding this one-time gain, operational PAT grew by 9% to ₹72 crores. The company continues to leverage its strong brands like Neurobion and Evion, maintaining a high ROCE of 84% and a very low debt-to-equity ratio of 0.02.
Confidence: HIGH
What changedPGHL reported its first-quarter results for FY 2026-27, showing steady operational growth and a significant one-time profit boost from an asset sale.
Why it mattersThe results confirm the resilience of the company's Vitamin, Mineral, and Supplement (VMS) portfolio and its ability to generate high returns (84% ROCE) while maintaining a nearly debt-free balance sheet.
Sales (Q1 FY27): ₹356 croresReported PAT (Q1 FY27): ₹96 croresOperational PAT (Q1 FY27): ₹72 croresSales Growth (YoY): 7%Operational PAT Growth (YoY): 9%ROCE: 84.0%
📅 Short termThe stock may see positive momentum due to the headline 45% PAT growth, although the market will likely adjust for the one-time asset sale gain.
📈 Long termThe company remains a strong player in the Indian VMS market with high capital efficiency; long-term growth depends on rural expansion and new product innovations.
⚠ Risk flags
- High product concentration in the Vitamin segment
- Pricing constraints due to Drug Price Control Order (DPCO) regulations
Key Highlights
Sales increased by 7% YoY to ₹356 crores for the quarter ended June 30, 2026.
Reported PAT grew 45% YoY to ₹96 crores, including one-time asset sale proceeds.
Operational PAT (excluding one-time items) rose 9% YoY to ₹72 crores.
The company maintains a high Return on Capital Employed (ROCE) of 84.0%.
Debt remains minimal at ₹9 crores against a net worth of ₹525 crores.
👀 What to Watch
Investors should monitor the sustainability of the 9% operational PAT growth and track how the company manages pricing under DPCO regulations to maintain margins in the VMS segment.
PGHL Q1 Results: Net Profit Rises 45% to ₹96.15 Cr, Aided by ₹31.8 Cr Property Sale
Procter & Gamble Health Limited (PGHL) reported a steady 7.4% YoY revenue growth to ₹363.71 Cr for the quarter ended June 30, 2026. Net profit surged 45.3% YoY to ₹96.15 Cr, though this was significantly bolstered by a one-time exceptional gain of ₹31.80 Cr from the sale of its Worli office premises. Excluding this gain, Profit Before Tax (PBT) stood at ₹97.31 Cr, a 9.6% increase over the ₹88.81 Cr reported in the same quarter last year. The company continues to operate with a very strong ROCE of 84% and minimal debt of ₹9 Cr.
Confidence: HIGH
What changedPGHL reported its quarterly financial results and completed the divestment of its Worli office premises, resulting in a significant one-time profit boost.
Why it mattersThe results demonstrate steady growth in the core pharmaceutical/VMS business, while the property sale strengthens the cash position of an already debt-free, high-ROCE company.
Revenue (Q1 FY27): ₹363.71 CrNet Profit (Q1 FY27): ₹96.15 CrExceptional Gain: ₹31.80 CrGain vs Net Worth: 6.06%YoY Revenue Growth: 7.37%
📅 Short termThe stock may see positive momentum due to the headline profit growth, though the market will likely adjust for the non-recurring nature of the property sale gain.
📈 Long termThe long-term outlook remains tied to the company's ability to expand its VMS portfolio and rural reach under its 'Integrated Growth Strategy' despite regulatory pricing pressures.
⚠ Risk flags
- High product concentration in the Vitamin segment
- Pricing constraints due to Drug Price Control Order (DPCO)
- One-time nature of the current profit surge
Key Highlights
Revenue from operations grew 7.4% YoY to ₹363.71 Cr from ₹338.74 Cr.
Net profit increased to ₹96.15 Cr, up from ₹66.18 Cr in the corresponding quarter last year.
Realized an exceptional gain of ₹31.80 Cr from the sale of Worli office property for ₹33.34 Cr.
Employee benefit expenses rose 7.8% YoY to ₹60.39 Cr.
Basic EPS (after exceptional items) improved to ₹57.92 from ₹39.87 YoY.
👀 What to Watch
Investors should focus on the core operational performance excluding the one-time property gain to assess sustainable growth. Watch for the impact of DPCO pricing regulations on margins in the upcoming quarters.
PGHL Announces ₹45 Final Dividend for FY 2025-26 and Issues TDS Guidelines
Procter & Gamble Health Limited (PGHL) has recommended a final dividend of ₹45 per equity share for the financial year 2025-26, subject to shareholder approval. The company has released detailed instructions regarding Tax Deducted at Source (TDS) on this dividend, which is taxable in the hands of shareholders. Resident shareholders with a valid PAN will be subject to a 10% TDS, while those without a valid PAN or linked Aadhaar will face a 20% deduction. Shareholders must submit relevant tax exemption documents or residency certificates by August 12, 2026, to ensure the correct tax rate is applied.
Key Highlights
Recommended a final dividend of ₹45 per equity share of face value ₹10 for FY 2025-26.
Standard TDS rate of 10% for resident shareholders with a valid PAN and linked Aadhaar.
Higher TDS rate of 20% for resident shareholders with invalid PAN or missing Aadhaar-PAN linkage.
No TDS for individual resident shareholders if the total dividend for the year does not exceed ₹10,000.
Deadline for submitting tax-related declarations and documents is August 12, 2026.
👀 What to Watch
Shareholders should verify that their PAN is correctly updated and linked with Aadhaar in their demat accounts to avoid a higher 20% tax deduction. Eligible investors seeking tax exemptions should submit Form 121 or other required documents on the KFintech portal before the August 12 deadline.
PGHL Reports 30% PAT Growth to ₹327 Crore in FY26; Sales Up 16% to ₹1,400 Crore
Procter & Gamble Health Limited (PGHL) delivered a robust financial performance for the fiscal year ended March 31, 2026, with sales reaching approximately ₹1,400 crore, a 16% year-on-year increase. Profit After Tax (PAT) surged by 30% to ₹327 crore, supported by a 16% growth in the top line and significant productivity gains. The company is focusing on 'irresistible superiority' through new launches like Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream to address high-prevalence health gaps in India. Management also reported ₹35 crore in productivity savings, which are being reinvested into brand building and margin expansion.
Key Highlights
Annual sales grew 16% YoY to reach approximately ₹1,400 crore for the fiscal year ended March 2026.
Profit After Tax (PAT) increased by 30% YoY to ₹327 crore, significantly outpacing revenue growth.
Achieved ₹35 crore in savings through targeted productivity and efficiency programs across the value chain.
Introduced high-potential innovations including Livogen Iron Gummies, Neurobion Nerve Pain Relief Cream, and Evion L5000.
Maintained strong market position in Vitamin B, Iron, and Vitamin E categories with brands like Neurobion, Livogen, and Evion.
👀 What to Watch
Investors should take note of the strong margin expansion and the company's ability to grow its bottom line at nearly double the rate of its top line. The successful rollout of new formats like gummies and topical creams indicates a strong innovation pipeline that could drive future market share gains.
PGHL Reports Strong FY26 Performance with 16% Sales Growth and 30% PAT Increase
Procter & Gamble Health Limited (PGHL) delivered robust performance for FY 2025-26, reporting a 16% increase in sales and a 30% surge in PAT on a comparable 12-month basis. The company achieved ₹35 crores in productivity savings during the fiscal year while maintaining a 5-year PAT CAGR of 13%. Management is aggressively targeting the Vitamins, Minerals, and Supplements (VMS) category, which is growing at a 9% CAGR in India, by expanding into extra-urban markets and quick-commerce channels.
Key Highlights
Delivered 16% sales growth and 30% PAT growth for FY 2025-26 compared to the previous 12-month period.
Achieved ₹35 crores in productivity savings across materials, manufacturing, and advertising spend.
Reported a 5-year Net Sales CAGR of 7% and a PAT CAGR of 13%, with a 42% increase in Return on Equity (ROE).
Revenue from operations reached ₹1,408 crores in FY 2026, up from ₹1,008 crores in FY 2021.
Strategic focus on 'Constructive Disruption' through expansion into extra-urban markets and emerging digital channels like Q-Com.
👀 What to Watch
Investors should note the significant margin improvement driven by productivity initiatives and the company's successful navigation of its fiscal year transition. The stock remains a strong long-term play on India's under-penetrated VMS market, especially given the 30% PAT growth.
PGHL Q4 PAT Surges 55% to ₹95 Cr; Total FY26 Dividend Declared at ₹205 Per Share
Procter & Gamble Health Limited (PGHL) reported a strong Q4 FY26 with sales growing 20% YoY to ₹365 crores and PAT jumping 55% to ₹95 crores. For the full fiscal year, the company achieved sales of ₹1385 crores and a PAT of ₹327 crores, representing a 16% and 30% growth respectively on a comparable 12-month basis. The Board has recommended a final dividend of ₹45 per share, which, combined with the interim dividend, brings the total FY26 payout to ₹205 per share. Growth was primarily driven by brand building, supply chain efficiencies, and new product launches in the VMS category.
Key Highlights
Q4 FY26 revenue increased 20% YoY to ₹365 crores with PAT rising 55% to ₹95 crores.
Full-year FY26 PAT reached ₹327 crores, up 30% compared to the previous 12-month period.
Total dividend for the fiscal year stands at ₹205 per share, including a final dividend of ₹45.
New product launches include Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream.
Company successfully transitioned its financial year cycle, maintaining strong double-digit growth across metrics.
👀 What to Watch
Investors should take note of the significant margin expansion and the high dividend yield, which underscores the company's strong cash flow. The stock remains a robust pick for those seeking exposure to the defensive healthcare and supplements sector with high shareholder returns.
PGHL Sets August 21, 2026, as Record Date for Dividend and 59th AGM
Procter & Gamble Health Limited (PGHL) has officially announced the record date for its upcoming dividend and 59th Annual General Meeting (AGM). The record date is fixed for August 21, 2026, which will determine the eligibility of shareholders to receive the dividend payment. The 59th AGM is scheduled to be held shortly after on August 27, 2026. The final dividend payout remains subject to the approval of shareholders during the meeting.
Key Highlights
Record date for dividend eligibility and 59th AGM is August 21, 2026
The 59th Annual General Meeting is scheduled for August 27, 2026
Dividend payment is contingent upon shareholder approval at the AGM
Official communication sent to both BSE and NSE regarding the timeline
👀 What to Watch
Investors interested in the dividend should ensure they hold the company's shares before the record date of August 21, 2026. Monitor the AGM outcomes on August 27 for final approval and payout details.
PGHL Recommends ₹45 Final Dividend; Total FY26 Payout Reaches ₹205 Per Share
Procter & Gamble Health Limited (PGHL) has recommended a final dividend of ₹45 per equity share for the financial year ended March 31, 2026. This brings the total dividend for the year to a substantial ₹205 per share, which includes a one-time special dividend of ₹160 declared in February 2026. For the full financial year, the company reported a net profit of ₹326.91 crore on revenue from operations of ₹1,407.97 crore. The company maintains a robust balance sheet with cash and cash equivalents totaling ₹177.40 crore.
Key Highlights
Recommended final dividend of ₹45 per share, bringing total FY26 dividend to ₹205 per share
Reported annual Revenue from Operations of ₹1,40,797 lakhs (₹1,407.97 crore)
Annual Net Profit stood at ₹32,691 lakhs (₹326.91 crore) with an EPS of ₹196.94
Quarterly Net Profit for Jan-Mar 2026 rose to ₹9,460 lakhs compared to ₹7,759 lakhs in the preceding quarter
Final dividend payment is scheduled to be completed on or before September 25, 2026
👀 What to Watch
Investors should view the high total dividend payout of ₹205 per share as a strong sign of capital return, though they should note the special dividend component is non-recurring. The stock remains a solid pick for dividend-seeking portfolios given the healthy cash flows and consistent profitability.
PGHL Reports FY26 Net Profit of ₹327 Crore; Total Dividend for Year Reaches ₹205 Per Share
Procter & Gamble Health Limited (PGHL) reported a net profit of ₹326.91 crore for the full financial year ended March 31, 2026, on a revenue of ₹1,407.97 crore. The Board has recommended a final dividend of ₹45 per share, bringing the total dividend for the year to a substantial ₹205 per share including previous interim and special payouts. Quarterly performance was robust, with Q4 net profit rising to ₹94.60 crore from ₹77.59 crore in the preceding quarter. Investors should note that year-on-year comparisons are limited as the previous financial year was a shortened nine-month period.
Key Highlights
Full-year FY26 revenue from operations stood at ₹1,40,797 lakhs with a net profit of ₹32,691 lakhs.
Recommended a final dividend of ₹45 per share, resulting in a total FY26 dividend of ₹205 per share.
Quarterly net profit for the period ended March 31, 2026, grew to ₹9,460 lakhs from ₹7,759 lakhs in the previous quarter.
Annual Earnings Per Share (EPS) reached ₹196.94 for the 12-month period ended March 2026.
Maintained a strong liquidity position with cash and cash equivalents totaling ₹17,740 lakhs.
👀 What to Watch
PGHL remains an attractive play for dividend-seeking investors given the high total payout of ₹205 per share. Shareholders should approve the final dividend in the upcoming AGM to realize the remaining ₹45 per share yield.
PGHL to Record INR 32 Crore Profit from Sale of Mumbai Real Estate Assets
Procter & Gamble Health Limited has announced the sale of immovable properties situated in Mumbai. The transaction, executed on April 30, 2026, is expected to generate a profit of approximately INR 32 Crores. This disposal of assets will provide a one-time boost to the company's other income and overall profitability. The move aligns with standard corporate practices of monetizing non-core or underutilized assets to strengthen the balance sheet.
Key Highlights
Sale of immovable properties in Mumbai executed on April 30, 2026
Estimated profit of approximately INR 32 Crores from the transaction
Compliance with Regulation 30 of SEBI (LODR) Regulations
👀 What to Watch
Investors should view this as a positive one-time gain that will boost the bottom line; however, focus should remain on core operational growth for long-term assessment.
PGHL Declares ₹160 Interim Dividend Including ₹50 Special Dividend
Procter & Gamble Health Limited has announced a substantial interim dividend of ₹160 per equity share for the financial year 2025-26. This total payout includes a one-time special dividend of ₹50 per share, signaling a significant cash distribution to shareholders. The record date for determining eligibility is set for February 12, 2026. Shareholders must ensure their tax documents and PAN details are updated by February 10, 2026, to avoid higher TDS deductions.
Key Highlights
Declared an interim dividend of ₹160 per equity share with a face value of ₹10 each.
The payout includes a one-time special dividend component of ₹50 per share.
The record date for determining shareholder eligibility is February 12, 2026.
Standard TDS of 10% applies for resident shareholders with PAN; 20% for those without.
Submission deadline for tax exemption forms (15G/15H) is February 10, 2026.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the record date of February 12, 2026. Existing shareholders should promptly submit tax-related declarations to the RTA by February 10 to optimize their net payout.
PGHL Q3 Net Profit Drops 14.6% to ₹77.6 Cr; Declares Massive ₹160 Interim Dividend
Procter & Gamble Health Limited (PGHL) reported a 20.7% YoY growth in revenue to ₹373.86 crore for the quarter ended December 31, 2025. Despite revenue growth, net profit declined by 14.6% YoY to ₹77.59 crore due to a significant 40% surge in total expenses, particularly in raw materials and employee benefits. To reward shareholders, the board declared a substantial interim dividend of ₹160 per share, which includes a ₹50 special dividend. The record date for this payout is February 12, 2026.
Key Highlights
Revenue from operations increased by 20.7% YoY to ₹373.86 crore from ₹309.77 crore.
Net profit for the quarter fell 14.6% YoY to ₹77.59 crore compared to ₹90.90 crore in the previous year.
Declared an interim dividend of ₹160 per equity share, including a one-time special dividend of ₹50.
Total expenses rose sharply to ₹269.40 crore from ₹192.04 crore in the corresponding quarter last year.
Nine-month net profit for the period ended December 2025 stands at ₹232.31 crore, up from ₹190.01 crore YoY.
👀 What to Watch
Investors should focus on the high dividend yield offered by the ₹160 payout, while keeping a close watch on rising operating costs that impacted quarterly margins. The stock is likely to attract yield-seeking investors ahead of the February 12 record date.
PGHL Q3 Sales Up 21% to ₹368 Cr; Declares ₹160 Interim Dividend per Share
Procter & Gamble Health Limited (PGHL) reported a strong 21% year-on-year growth in sales, reaching ₹368 crores for the quarter ended December 31, 2025. The company's Profit After Tax (PAT) stood at ₹78 crores, driven by robust brand fundamentals and new product innovations like Livogen Iron Gummies. A major highlight for shareholders is the declaration of an interim dividend of ₹160 per equity share, which includes a ₹50 special dividend. This performance underscores the company's leadership in the vitamins, minerals, and supplements (VMS) category in India.
Key Highlights
Sales for the quarter ended December 31, 2025, rose 21% YoY to ₹368 crores.
Profit After Tax (PAT) for the quarter reached ₹78 crores.
Declared an interim dividend of ₹160 per share, including a one-time special dividend of ₹50.
Growth supported by new innovations including Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream.
Strong top-line momentum maintained from the first half of the financial year 2025-26.
👀 What to Watch
Investors should take note of the significant dividend payout and strong revenue growth as signs of a healthy cash-rich business. The stock remains a solid play in the VMS segment with high brand equity in products like Neurobion and Evion.
PGHL Declares Rs 160 Interim Dividend; Q3 Revenue Up 20.7% YoY to Rs 373.86 Cr
Procter & Gamble Health Limited has declared a substantial interim dividend of Rs 160 per share, which includes a one-time special dividend of Rs 50. For the quarter ended December 31, 2025, revenue grew 20.7% YoY to Rs 373.86 crore, although net profit declined 14.6% to Rs 77.59 crore due to higher operating expenses. The nine-month performance remains strong with a net profit of Rs 232.31 crore compared to Rs 190.01 crore in the previous year. The record date for the dividend is fixed as February 12, 2026.
Key Highlights
Declared an interim dividend of Rs 160 per equity share, including a Rs 50 special dividend
Q3 Revenue from operations rose 20.7% YoY to Rs 373.86 crore from Rs 309.77 crore
Net profit for the quarter dipped to Rs 77.59 crore from Rs 90.90 crore YoY due to increased expenses
Nine-month net profit increased to Rs 232.31 crore from Rs 190.01 crore in the corresponding previous period
Record date for dividend eligibility is February 12, 2026, with payment by March 4, 2026
👀 What to Watch
Investors seeking high dividend yields should ensure they hold shares before the February 12 record date. While quarterly margins were pressured by costs, the overall nine-month growth and high payout ratio remain attractive for long-term holders.
PGHL Declares ₹160 Interim Dividend; Q3 Revenue Rises 20.7% to ₹373.86 Crore
Procter & Gamble Health Limited (PGHL) has declared a significant interim dividend of ₹160 per share, which includes a ₹50 special dividend. For the quarter ended December 31, 2025, the company reported a 20.7% YoY increase in revenue to ₹373.86 crore. However, net profit for the quarter saw a decline of 14.6% YoY to ₹77.59 crore due to increased operational expenses. Despite the quarterly profit dip, the nine-month profit for the period ending December 2025 remains strong at ₹232.31 crore, up from ₹190.01 crore in the previous year.
Key Highlights
Declared interim dividend of ₹160 per equity share, including a one-time special dividend of ₹50.
Revenue from operations grew to ₹373.86 crore in Q3 FY26 from ₹309.77 crore in Q3 FY25.
Net profit for the quarter stood at ₹77.59 crore, down from ₹90.90 crore in the corresponding previous quarter.
Nine-month net profit showed healthy growth, reaching ₹232.31 crore compared to ₹190.01 crore YoY.
Record date for dividend eligibility is fixed as February 12, 2026, with payment by March 4, 2026.
👀 What to Watch
Investors should ensure they hold shares by the February 12 record date to benefit from the high dividend payout. While quarterly margins were pressured, the overall nine-month growth and strong dividend policy reflect a stable financial position.
PGHL Declares Rs 160 Interim Dividend; Q3 Revenue Rises 20.7% to Rs 373.9 Crore
Procter & Gamble Health Limited (PGHL) has announced a significant interim dividend of Rs 160 per share, which includes a one-time special dividend of Rs 50. For the quarter ended December 31, 2025, the company reported a 20.7% YoY increase in revenue to Rs 373.86 crore. However, quarterly net profit declined by 14.6% YoY to Rs 77.59 crore, impacted by a sharp rise in employee benefits and other operational expenses. Despite the quarterly profit dip, the nine-month performance remains robust with a 22.3% growth in net profit to Rs 232.31 crore.
Key Highlights
Declared interim dividend of Rs 160 per equity share, including a Rs 50 special dividend.
Q3 Revenue from operations grew 20.7% YoY to Rs 37,386 lakhs.
Nine-month Net Profit increased by 22.3% YoY to Rs 23,231 lakhs.
Total expenses for the quarter rose significantly to Rs 26,940 lakhs from Rs 19,204 lakhs in the previous year.
Record date for dividend eligibility is fixed as February 12, 2026, with payment by March 4, 2026.
👀 What to Watch
Investors should ensure they hold shares by the February 12 record date to qualify for the substantial dividend payout. While quarterly margins were pressured by higher costs, the strong nine-month growth and high dividend yield remain attractive for income-seeking investors.
